Prothena Corporation plc : Prothena Announces Public Offering of Ordinary Shares
(Thomson Reuters ONE) -
DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
today announced that it has commenced a registered underwritten public offering
of 2,700,000 of its ordinary shares. All of the ordinary shares in the offering
will be sold by Prothena. In addition, Prothena has granted the underwriter a
30-day option to purchase up to an additional 405,000 of its ordinary shares.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for the offering.
The ordinary shares of Prothena described above are being offered only by means
of a prospectus supplement and base prospectus forming part of an effective
shelf registration statement filed with the Securities and Exchange Commission.
Copies of the prospectus for this offering may be obtained, when available, by
contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th
Floor, New York, New York 10022, or by telephone at 212-829-7122, or by e-mail
at prospectus(at)cantor.com.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or other jurisdiction.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company
with a clinical pipeline of novel therapeutic antibodies. Prothena is
establishing a fully integrated research, development and commercial focus and
has advanced several drug candidates into clinical studies while pursuing
discovery of additional novel therapies. Our pipeline of antibody-based product
candidates targets a number of potential indications including AL amyloidosis
(NEOD001), Parkinson's disease and other related synucleinopathies (PRX002),
inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and
ATTR amyloidosis (PRX004).
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate
to, among other things, the timing and size of the proposed offering, the
conditions affecting the capital markets, general economic, industry, or
political conditions, and the satisfaction of customary closing conditions
related to the proposed offering. These statements are based on estimates,
projections and assumptions that may prove not to be accurate, and actual
results could differ materially from those anticipated due to known and unknown
risks, uncertainties and other factors, including but not limited to the risks,
uncertainties and other factors described in the "Risk Factors" sections of
Prothena's Annual Report on Form 10-K filed with the Securities and Exchange
Commission (SEC) on February 27, 2017 and in the preliminary prospectus
supplement related to the proposed offering to be filed with the SEC on or about
the date hereof. Prothena undertakes no obligation to update publicly any
forward-looking statements contained in this press release as a result of new
information, future events or changes in Prothena's expectations.
Contact
Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Ellen Rose, Head of Communications
650-922-2405, ellen.rose(at)prothena.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.03.2017 - 22:01 Uhr
Sprache: Deutsch
News-ID 527900
Anzahl Zeichen: 4348
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 145 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena Corporation plc : Prothena Announces Public Offering of Ordinary Shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
